Addressing the Challenges of Treating Patients with Heterozygous Gain of Function Mutations
Crooke, S.T.
Safety and Tolerability of GalNAc3-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data
Baker B.F., Xia, S., Partridge, W., Engelhardt, J.A., Tsimikas, S., Crooke, S.T., Bhanot, S., Geary, R.S. Download PDF
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
Crooke, S.T., Baker B.F., Xia, S., Yu., R.Z., Viney, N.J., Wang, Y., Tsimikas, S., Geary, R.S. Download PDF
The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
Crooke, S.T., Baker, B.F., Pham, N.C., Hughes, S.G., Kwoh, T.J., Cai, D., Tsimikas, S., Geary, R.S., Bhanot, S. Download PDF
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Crooke, S.T., Baker, B.F., Witztum, J.L., Kwoh, T.J., Pham, N.C., Salgado, N., McEvoy, B.W., Cheng, W., Hughes, S.G., Bhanot, S., Geary, R.S. Download PDF
